Personalizing treatments for patients based on cardiovascular phenotyping

References

• Virani SS, Alonso A, Benjamin EJ, et al Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596.
   PubMed Web of Science ®Google Scholar
• Blackwell DL, Villarroel MA. Tables of summary health statistics for US adults: 2017 National Health Interview Survey. Centers for Disease Control and Prevention; 2018. http://www.cdc.gov/nchs/nhis/SHS/tables.htm.
   Google Scholar
• Global Burden of Cardiovascular Diseases Collaboration, Roth GA, Johnson CO, et al. The burden of cardiovascular diseases among US States, 1990-2016. JAMA Cardiol 2018;3(5):375–389.
   PubMed Web of Science ®Google Scholar
• Snyderman R, Meade C, Drake C. Value of Personalized Medicine. JAMA. 2016;315(6):613.
   PubMedGoogle Scholar
• Snyderman R, Dreke CD. Personalized health care: unlocking the potential of genomic and precision medicine. J Precis Med. 2015;1:38–41.
   Google Scholar
• Naylor S. What’s in a name? THe evolution of P-medicine. J Precis Med. 2015;1:15–29.
   Google Scholar
• Leopold JA, Loscalzo J. Emerging role of precision medicine in cardiovascular disease. Circ Res. 2018;122(9):1302–1315.
   PubMed Web of Science ®Google Scholar
• Bhatnagar A. Environmental determinants of cardiovascular disease. Circ Res. 2017;121(2):162–180.
   PubMed Web of Science ®Google Scholar
• Abdulrahim JW, Kwee LC, Alenezi F, et al Identification of undetected monogenic cardiovascular disorders. J Am Coll Cardiol. 2020;76(7):797–808.
   PubMed Web of Science ®Google Scholar
• Helgadottir A, Thorleifsson G, Manolescu A, et al A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316(5830):1491–1493.
   PubMed Web of Science ®Google Scholar
• McPherson R, Pertsemlidis A, Kavaslar N, et al A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316(5830):1488–1491.
   PubMed Web of Science ®Google Scholar
• Samani NJ, Erdmann J, Hall AS, et al Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357(5):443–453.
   PubMed Web of Science ®Google Scholar
• Leopold JA, Maron BA, Loscalzo J. The application of big data to cardiovascular disease: paths to precision medicine. J Clin Invest. 2020;130(1):29–38.
   PubMed Web of Science ®Google Scholar
• Nikpay M, Goel A, Won HH, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121–1130.
   PubMed Web of Science ®Google Scholar
• Franceschini N, Giambartolomei C, de Vries PS, et al GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes. Nat Commun. 2018;9(1):5141.
   PubMedGoogle Scholar
• Surendran P, Drenos F, Young R, et al Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat Genet. 2016;48(10):1151–1161.
   PubMed Web of Science ®Google Scholar
• Levy D, Ehret GB, Rice K, et al Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009;41(6):677–687.
   PubMed Web of Science ®Google Scholar
• Evangelou E, Warren HR, Mosen-Ansorena D, et al Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50(10):1412–1425.
   PubMed Web of Science ®Google Scholar
• Warren HR, Evangelou E, Cabrera CP, et al Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet. 2017;49(3):403–415.
   PubMed Web of Science ®Google Scholar
• Doherty A, Smith-Byrne K, Ferreira T, et al GWAS identifies 14 loci for device-measured physical activity and sleep duration. Nat Commun. 2018;9(1):5257.
   PubMedGoogle Scholar
• Khera AV, Emdin CA, Drake I, et al Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med. 2016;375(24):2349–2358.
   PubMed Web of Science ®Google Scholar
• Taliun D, Harris DN, Kessler Md, et al Sequencing of 53,831 diverse genomes from the NHLBI TOPMed program. Nature. 2021;590(7845):290–299.
   PubMed Web of Science ®Google Scholar
• Richard MA, Huan T, Ligthart S, et al DNA methylation analysis identifies loci for blood pressure regulation. Am J Hum Genet. 2017;101(6):888–902.
   PubMed Web of Science ®Google Scholar
• Huang Y, Ollikainen M, Muniandy M, et al Identification, heritability, and relation with gene expression of novel DNA methylation loci for blood pressure. Hypertension. 2020;76(1):195–205.
   PubMed Web of Science ®Google Scholar
• Zeller T, Schurmann C, Schramm K, et al Transcriptome-wide analysis identifies novel associations with blood pressure. Hypertension. 2017;70(4):743–750.
   PubMed Web of Science ®Google Scholar
• Hartman RJG, Kapteijn DMC, Haitjema S, et al Intrinsic transcriptomic sex differences in human endothelial cells at birth and in adults are associated with coronary artery disease targets. Sci Rep. 2020;10(1):12367.
   PubMed Web of Science ®Google Scholar
• McManus DD, Rong J, Huan T, et al Messenger RNA and MicroRNA transcriptomic signatures of cardiometabolic risk factors. BMC Genomics. 2017;18(1):139.
   PubMedGoogle Scholar
• Herrington DM, Mao C, Parker SJ, et al Proteomic architecture of human coronary and aortic atherosclerosis. Circulation. 2018;137(25):2741–2756.
   PubMed Web of Science ®Google Scholar
• Fernandez DM, Rahman AH, Fernandez NF, et al Single-cell immune landscape of human atherosclerotic plaques. Nat Med. 2019;25(10):1576–1588.
   PubMed Web of Science ®Google Scholar
• Ho JE, Lyass A, Courchesne P, et al. Protein biomarkers of cardiovascular disease and mortality in the community. J Am Heart Assoc. 2018;7(14). DOI:10.1161/JAHA.117.008108.
   Web of Science ®Google Scholar
• Benson MD, Yang Q, Ngo D, et al Genetic architecture of the cardiovascular risk proteome. Circulation. 2018;137(11):1158–1172.
   PubMed Web of Science ®Google Scholar
• Lau ES, Paniagua SM, Guseh JS, et al Sex differences in circulating biomarkers of cardiovascular disease. J Am Coll Cardiol. 2019;74(12):1543–1553.
   PubMed Web of Science ®Google Scholar
• Ganz P, Heidecker B, Hveem K, et al Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. 2016;315(23):2532–2541.
   PubMed Web of Science ®Google Scholar
• Unterhuber M, Kresoja KP, Rommel KP, et al Proteomics-Enabled Deep Learning Machine Algorithms Can Enhance Prediction of Mortality. J Am Coll Cardiol. 2021;78(16):1621–1631.
   PubMed Web of Science ®Google Scholar
• Hoogeveen RM, Pereira JPB, Nurmohamed NS, et al Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. Eur Heart J. 2020;41(41):3998–4007.
   PubMed Web of Science ®Google Scholar
• Mosley JD, Benson MD, Smith JG, et al Probing the virtual proteome to identify novel disease biomarkers. Circulation. 2018;138(22):2469–2481.
   PubMed Web of Science ®Google Scholar
• Ngo D, Sinha S, Shen D, et al Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease. Circulation. 2016;134(4):270–285.
   PubMed Web of Science ®Google Scholar
• Nayor M, Short MI, Rasheed H, et al Aptamer-based proteomic platform identifies novel protein predictors of incident heart failure and echocardiographic traits. Circ Heart Fail. 2020;13(5):e006749.
   PubMed Web of Science ®Google Scholar
• Egerstedt A, Berntsson J, Smith ML, et al Profiling of the plasma proteome across different stages of human heart failure. Nat Commun. 2019;10(1):5830.
   PubMedGoogle Scholar
• Ferreira JP, Verdonschot J, Collier T, et al Proteomic bioprofiles and mechanistic pathways of progression to heart failure. Circ Heart Fail. 2019;12(5):e005897.
   PubMed Web of Science ®Google Scholar
• Adamo L, Yu J, Rocha-Resende C, et al Proteomic signatures of heart failure in relation to left ventricular ejection fraction. J Am Coll Cardiol. 2020;76(17):1982–1994.
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Castagne R, Boulange CL, et al Serum metabolic signatures of coronary and carotid atherosclerosis and subsequent cardiovascular disease. Eur Heart J. 2019;40(34):2883–2896.
   PubMed Web of Science ®Google Scholar
• Fan Y, Li Y, Chen Y, et al Comprehensive metabolomic characterization of coronary artery diseases. J Am Coll Cardiol. 2016;68(12):1281–1293.
   PubMed Web of Science ®Google Scholar
• Wurtz P, Havulinna AS, Soininen P, et al Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation. 2015;131(9):774–785.
   PubMed Web of Science ®Google Scholar
• Poss AM, Maschek JA, Cox JE, et al Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease. J Clin Invest. 2020;130(3):1363–1376.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wei TT, Li Y, et al Functional metabolomics characterizes a key role for N-acetylneuraminic acid in coronary artery diseases. Circulation. 2018;137(13):1374–1390.
   PubMed Web of Science ®Google Scholar
• Cheng S, Larson MG, McCabe EL, et al Distinct metabolomic signatures are associated with longevity in humans. Nat Commun. 2015;6(1):6791.
   PubMedGoogle Scholar
• Murthy VL, Reis JP, Pico AR, et al Comprehensive metabolic phenotyping refines cardiovascular risk in young adults. Circulation. 2020;142(22):2110–2127.
   PubMed Web of Science ®Google Scholar
• He WJ, Li C, Mi X, et al An untargeted metabolomics study of blood pressure: findings from the Bogalusa Heart Study. J Hypertens. 2020;38(7):1302–1311.
   PubMed Web of Science ®Google Scholar
• Tahir UA, Katz DH, Zhao T, et al Metabolomic profiles and heart failure risk in black adults: insights from the Jackson Heart Study. Circ Heart Fail. 2021;14(1):e007275.
   PubMed Web of Science ®Google Scholar
• Andersson C, Johnson AD, Benjamin EJ, et al 70-year legacy of the Framingham Heart Study. Nat Rev Cardiol. 2019;16(11):687–698.
   PubMed Web of Science ®Google Scholar
• Rose SM S-F, Contrepois K, Moneghetti KJ, et al A longitudinal big data approach for precision health. Nat Med. 2019;25(5):792–804.
   PubMed Web of Science ®Google Scholar
• Contrepois K, Wu S, Moneghetti KJ, et al Molecular choreography of acute exercise. Cell. 2020;181(5):1112–1130 e1116.
   PubMed Web of Science ®Google Scholar
• Katz DH, Tahir UA, Bick AG, et al. Whole genome sequence analysis of the plasma proteome in black adults provides novel insights into cardiovascular disease. Circulation. 2021. DOI:10.1161/CIRCULATIONAHA.121.055117.
   Web of Science ®Google Scholar
• Ritchie SC, Lambert SA, Arnold M, et al Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases. Nat Metab. 2021;3(11):1476–1483.
   PubMedGoogle Scholar
• Oqueli E, Hiscock M, Dick R. Clopidogrel resistance. Heart Lung Circ. 2007;16(5):S17–28.
   PubMedGoogle Scholar
• Ahmad T, Voora D, Becker RC. The pharmacogenetics of antiplatelet agents: towards personalized therapy?. Nat Rev Cardiol. 2011;8(10):560–571.
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A, et al Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309–317.
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–362.
   PubMed Web of Science ®Google Scholar
• Mega JL, Hochholzer W, Frelinger AL, et al Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306(20):2221–2228.
   PubMed Web of Science ®Google Scholar
• Geisler T, Schaeffeler E, Dippon J, et al CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics. 2008;9(9):1251–1259.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Koch W, Gebhard D, et al Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121(4):512–518.
   PubMed Web of Science ®Google Scholar
• Koopmans AB, Braakman MH, Vinkers DJ, et al Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Transl Psychiatry. 2021;11(1):141.
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, et al Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097–1105.
   PubMed Web of Science ®Google Scholar
• Pereira NL, Rihal C, Lennon R, et al Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis. JACC Cardiovasc Interv. 2021;14(7):739–750.
   PubMed Web of Science ®Google Scholar
• Wang Y, Meng X, Wang A, et al Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med. 2021;385(27):2520–2530.
   PubMed Web of Science ®Google Scholar
• International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360(8):753–764.
   PubMed Web of Science ®Google Scholar
• Zabalza M, Subirana I, Sala J, et al Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart. 2012;98(2):100–108.
   PubMed Web of Science ®Google Scholar
• Cooper-dehoff RM, Johnson JA. Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol. 2016;12(2):110–122.
   PubMed Web of Science ®Google Scholar
• Jorgensen AL, FitzGerald RJ, Oyee J, et al Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One. 2012;7(8):e44064.
   PubMed Web of Science ®Google Scholar
• Cooper GM, Johnson JA, Langaee TY, et al A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 2008;112(4):1022–1027.
   PubMed Web of Science ®Google Scholar
• Takeuchi F, McGinnis R, Bourgeois S, et al A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5(3):e1000433.
   PubMed Web of Science ®Google Scholar
• Kimmel SE, French B, Kasner SE, et al A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–2293.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Burnside G, Eriksson N, et al A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–2303.
   PubMed Web of Science ®Google Scholar
• Ross S, Nejat S, Pare G. Use of genetic data to guide therapy in arterial disease. J Thromb Haemost. 2015;13(1):S281–289.
   PubMedGoogle Scholar
• Wei MY, Ito MK, Cohen JD, et al Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–483.
   PubMed Web of Science ®Google Scholar
• SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med 2008;359(8):789–799.
   PubMed Web of Science ®Google Scholar
• Linskey DW, English JD, Perry DA, et al Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms. Pharmacogenet Genomics. 2020;30(9):208–211.
   PubMed Web of Science ®Google Scholar
• Hopewell JC, Offer A, Haynes R, et al Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. Eur Heart J. 2020;41(35):3336–3342.
   PubMed Web of Science ®Google Scholar
• Carr DF, Francis B, Jorgensen AL, et al Genomewide association study of statin-induced myopathy in patients recruited using the UK clinical practice research datalink. Clin Pharmacol Ther. 2019;106(6):1353–1361.
   PubMed Web of Science ®Google Scholar
• Zaiou M, El Amri H. Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine. Clin Genet. 2017;91(3):355–370.
   PubMed Web of Science ®Google Scholar
• Nielsen JB, Rom O, Surakka I, et al Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease. Nat Commun. 2020;11(1):6417.
   PubMed Web of Science ®Google Scholar
• Liu J, Lahousse L, Nivard MG, et al Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas. Nat Med. 2020;26(1):110–117.
   PubMed Web of Science ®Google Scholar
• Wikoff WR, Frye RF, Zhu H, et al Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One. 2013;8(3):e57639.
   PubMed Web of Science ®Google Scholar
• Rotroff DM, Shahin MH, Gurley SB, et al Pharmacometabolomic assessments of atenolol and hydrochlorothiazide treatment reveal novel drug response phenotypes. CPT Pharmacometrics Syst Pharmacol. 2015;4(11):669–679.
   PubMedGoogle Scholar
• Shahin MH, Gong Y, Frye RF, et al. Sphingolipid metabolic pathway impacts thiazide diuretics blood pressure response: insights from genomics, metabolomics, and lipidomics. J Am Heart Assoc. 2017;7(1). DOI:10.1161/JAHA.117.006656.
   PubMed Web of Science ®Google Scholar
• de Oliveira FA, Shahin MH, Gong Y, et al. Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. Metabolomics. 2016;12(8). DOI:10.1007/s11306-016-1076-8.
   PubMed Web of Science ®Google Scholar
• Weng L, Gong Y, Culver J, et al. Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. Metabolomics. 2016;12(10). DOI:10.1007/s11306-016-1098-2.
   PubMed Web of Science ®Google Scholar
• Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56–68.
   PubMed Web of Science ®Google Scholar
• Guney E, Menche J, Vidal M, et al Network-based in silico drug efficacy screening. Nat Commun. 2016;7(1):10331.
   PubMedGoogle Scholar
• Cheng F, Lu W, Liu C, et al A genome-wide positioning systems network algorithm for in silico drug repurposing. Nat Commun. 2019;10(1):3476.
   PubMedGoogle Scholar
• Cheng F, Desai RJ, Handy DE, et al Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9(1):2691.
   PubMed Web of Science ®Google Scholar
• Elliott LS, Henderson JC, Neradilek MB, et al Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. PLoS One. 2017;12(2):e0170905.
   PubMed Web of Science ®Google Scholar
• Aryan Z, Szanto A, Pantazi A, et al Moving genomics to routine care: an initial pilot in acute cardiovascular disease. Circ Genom Precis Med. 2020;13(5):406–416.
   PubMed Web of Science ®Google Scholar
• Antman EM, Cohen M, Bernink PJ, et al The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835–842.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Wilson PW, Larson MG, et al Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94(1):20–24.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabes JP, et al Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34–47.
   PubMed Web of Science ®Google Scholar
• Lehrman MA, Russell DW, Goldstein JL, et al Exon-Alu recombination deletes 5 kilobases from the low density lipoprotein receptor gene, producing a null phenotype in familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1986;83(11):3679–3683.
   PubMed Web of Science ®Google Scholar
• Lehrman MA, Schneider WJ, Sudhof TC, et al Mutation in LDL receptor: alu-Alu recombination deletes exons encoding transmembrane and cytoplasmic domains. Science. 1985;227(4683):140–146.
   PubMed Web of Science ®Google Scholar
• Brooks-Wilson A, Marcil M, Clee SM, et al Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22(4):336–345.
   PubMed Web of Science ®Google Scholar
• Bodzioch M, Orso E, Klucken J, et al The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999;22(4):347–351.
   PubMed Web of Science ®Google Scholar
• Rust S, Rosier M, Funke H, et al Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22(4):352–355.
   PubMed Web of Science ®Google Scholar
• Schultheiss HP, Fairweather D, Caforio ALP, et al Dilated cardiomyopathy. Nat Rev Dis Primers. 2019;5(1):32.
   PubMedGoogle Scholar
• McNally EM, Mestroni L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ Res. 2017;121(7):731–748.
   PubMed Web of Science ®Google Scholar
• Haas J, Frese KS, Peil B, et al Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2015;36(18):1123–1135a.
   PubMed Web of Science ®Google Scholar
• Fatkin D, MacRae C, Sasaki T, et al Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999;341(23):1715–1724.
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Kelly MA, Gowrisankar S, et al The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med. 2014;16(8):601–608.
   PubMed Web of Science ®Google Scholar
• Tobita T, Nomura S, Fujita T, et al Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci Rep. 2018;8(1):1998.
   PubMedGoogle Scholar
• Seeger T, Shrestha R, Lam CK, et al A premature termination codon mutation in MYBPC3 causes hypertrophic cardiomyopathy via chronic activation of nonsense-mediated decay. Circulation. 2019;139(6):799–811.
   PubMed Web of Science ®Google Scholar
• Marian AJ. Molecular genetic basis of hypertrophic cardiomyopathy. Circ Res. 2021;128(10):1533–1553.
   PubMed Web of Science ®Google Scholar
• Ho CY, Day SM, Ashley EA, et al Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe). Circulation. 2018;138(14):1387–1398.
   PubMed Web of Science ®Google Scholar
• Lopes LR, Syrris P, Guttmann OP, et al Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart. 2015;101(4):294–301.
   PubMed Web of Science ®Google Scholar
• Coppini R, Ho CY, Ashley E, et al Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations. J Am Coll Cardiol. 2014;64(24):2589–2600.
   PubMed Web of Science ®Google Scholar
• James CA, Syrris P, van Tintelen JP, et al The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy. Eur Heart J. 2020;41(14):1393–1400.
   PubMed Web of Science ®Google Scholar
• McKoy G, Protonotarios N, Crosby A, et al Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet. 2000;355(9221):2119–2124.
   PubMed Web of Science ®Google Scholar
• van Lint FHM, Murray B, Tichnell C, et al Arrhythmogenic right ventricular cardiomyopathy-associated desmosomal variants are rarely de novo. Circ Genom Precis Med. 2019;12(8):e002467.
   PubMed Web of Science ®Google Scholar
• Dietz HC, Cutting GR, Pyeritz RE, et al Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352(6333):337–339.
   PubMed Web of Science ®Google Scholar
• Arnaud P, Milleron O, Hanna N, et al Clinical relevance of genotype-phenotype correlations beyond vascular events in a cohort study of 1500 Marfan syndrome patients with FBN1 pathogenic variants. Genet Med. 2021;23(7):1296–1304.
   PubMed Web of Science ®Google Scholar
• McKusick VA. The cardiovascular aspects of Marfan’s syndrome: a heritable disorder of connective tissue. Circulation. 1955;11(3):321–342.
   PubMed Web of Science ®Google Scholar
• Milewicz DM, Braverman AC, De Backer J, et al Marfan syndrome. Nat Rev Dis Primers. 2021;7(1):64.
   PubMed Web of Science ®Google Scholar
• Pepin M, Schwarze U, Superti-Furga A, et al Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342(10):673–680.
   PubMed Web of Science ®Google Scholar
• Pepin MG, Schwarze U, Rice KM, et al Survival is affected by mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV). Genet Med. 2014;16(12):881–888.
   PubMed Web of Science ®Google Scholar
• Loeys BL, Chen J, Neptune ER, et al A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37(3):275–281.
   PubMed Web of Science ®Google Scholar
• van de Laar IM, Oldenburg RA, Pals G, et al Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet. 2011;43(2):121–126.
   PubMed Web of Science ®Google Scholar
• MacFarlane EG, Parker SJ, Shin JY, et al Lineage-specific events underlie aortic root aneurysm pathogenesis in Loeys-Dietz syndrome. J Clin Invest. 2019;129(2):659–675.
   PubMed Web of Science ®Google Scholar
• Lerner-Ellis JP, Aldubayan SH, Hernandez AL, et al The spectrum of FBN1, TGFbetaR1, TGFbetaR2 and ACTA2 variants in 594 individuals with suspected Marfan syndrome, loeys-dietz syndrome or Thoracic Aortic Aneurysms and Dissections (TAAD). Mol Genet Metab. 2014;112(2):171–176.
   PubMed Web of Science ®Google Scholar
• Bertoli-Avella AM, Gillis E, Morisaki H, et al Mutations in a TGF-beta ligand, TGFB3, cause syndromic aortic aneurysms and dissections. J Am Coll Cardiol. 2015;65(13):1324–1336.
   PubMed Web of Science ®Google Scholar
• Coady MA, Davies RR, Roberts M, et al Familial patterns of thoracic aortic aneurysms. Arch Surg. 1999;134(4):361–367.
   PubMedGoogle Scholar
• Guo DC, Papke CL, Tran-Fadulu V, et al Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet. 2009;84(5):617–627.
   PubMed Web of Science ®Google Scholar
• Pomianowski P, Elefteriades JA. The genetics and genomics of thoracic aortic disease. Ann Cardiothorac Surg. 2013;2(3):271–279.
   PubMedGoogle Scholar
• Giusti B, Sticchi E, De Cario R, et al Genetic bases of bicuspid aortic valve: the contribution of traditional and high-throughput sequencing approaches on research and diagnosis. Front Physiol. 2017;8:612.
   PubMed Web of Science ®Google Scholar
• Chen Q, Kirsch GE, Zhang D, et al Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998;392(6673):293–296.
   PubMed Web of Science ®Google Scholar
• Brugada J, Campuzano O, Arbelo E, et al Present status of brugada syndrome: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(9):1046–1059.
   PubMed Web of Science ®Google Scholar
• Sarquella-Brugada G, Campuzano O, Arbelo E, et al Brugada syndrome: clinical and genetic findings. Genet Med. 2016;18(1):3–12.
   PubMed Web of Science ®Google Scholar
• Giudicessi JR, Wilde AAM, Ackerman MJ. The genetic architecture of long QT syndrome: a critical reappraisal. Trends Cardiovasc Med. 2018;28(7):453–464.
   PubMed Web of Science ®Google Scholar
• Neira V, Enriquez A, Simpson C, et al Update on long QT syndrome. J Cardiovasc Electrophysiol. 2019;30(12):3068–3078.
   PubMed Web of Science ®Google Scholar
• Southgate L, Machado RD, Graf S, et al Molecular genetic framework underlying pulmonary arterial hypertension. Nat Rev Cardiol. 2020;17(2):85–95.
   PubMed Web of Science ®Google Scholar
• Graf S, Haimel M, Bleda M, et al Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun. 2018;9(1):1416.
   PubMedGoogle Scholar
• Bohnen MS, Ma L, Zhu N, et al Loss-of-function ABCC8 mutations in pulmonary arterial hypertension. Circ Genom Precis Med. 2018;11(10):e002087.
   PubMed Web of Science ®Google Scholar
• Eyries M, Coulet F, Girerd B, et al ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension. Clin Genet. 2012;82(2):173–179.
   PubMed Web of Science ®Google Scholar
• Eyries M, Montani D, Girerd B, et al Familial pulmonary arterial hypertension by KDR heterozygous loss of function. Eur Respir J. 2020;55(4):1902165.
   PubMed Web of Science ®Google Scholar
• Zhu N, Swietlik EM, Welch CL, et al Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Med. 2021;13(1):80.
   PubMed Web of Science ®Google Scholar
• Swietlik EM, Greene D, Zhu N, et al. Bayesian inference associates rare KDR variants with specific phenotypes in pulmonary arterial hypertension. Circ Genom Precis Med; 2020.
   Google Scholar
• Newman JH, Wheeler L, Lane KB, et al Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med. 2001;345(5):319–324.
   PubMed Web of Science ®Google Scholar
• Eyries M, Montani D, Girerd B, et al EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2014;46(1):65–69.
   PubMed Web of Science ®Google Scholar
• Hadinnapola C, Bleda M, Haimel M, et al Phenotypic characterization of EIF2AK4 mutation carriers in a large cohort of patients diagnosed clinically with pulmonary arterial hypertension. Circulation. 2017;136(21):2022–2033.
   PubMed Web of Science ®Google Scholar